China NMPA Product Recall - Concentrates for hemodialysis and related treatments

Shanghai Heting Trading Co., Ltd. has initiated a voluntary Class III recall for its hemodialysis and related therapeutic concentrates. This decision stems from findings of a national sampling inspection conducted on May 13, 2020, overseen by the National Medical Products Administration (NMPA). The subsequent test report, issued on August 10, 2020, concluded that the product was 'unqualified,' with specific concerns noted regarding fill volume. The recall notice was publicly released on August 14, 2020, facilitated by the Shanghai Municipal Drug Administration. A Class III recall indicates that the product is unlikely to cause adverse health consequences but still represents a deviation from regulatory standards. This proactive measure by Shanghai Heting Trading Co., Ltd. underscores the company's commitment to addressing product deficiencies identified through regulatory oversight. The recall process ensures that affected batches, identified by Registration Certificate No. 国械注准20163451473, are removed from distribution. Further specifics regarding the models, specifications, and batch numbers involved are detailed in the 'Medical Device Recall Event Report Form' made available by the NMPA. This event highlights the continuous regulatory scrutiny in place to safeguard public health in the medical device sector.